July 28, 2025 – Terumo Blood and Cell Technologies (Terumo BCT) and Eureka Biotechnology Co., Ltd. (EurekaBio) have announced a significant advancement in the ongoing collaboration to transform CAR-T cell therapy manufacturing. Together, we have developed and validated a closed, automated "three-in-one" platform that integrates T cell activation, viral transduction, and expansion into a single hollow-fiber bioreactor system. This groundbreaking process is now published in Cytotherapy, a leading journal in the field of cell and gene therapy.

A New Standard: Integrated Automation from Apheresis fo Final Product in 8 Days

The validated workflow brings together Terumo's Spectra Optia® for T cell collection, the Quantum™ Cell Expansion System for three-step CAR-T bioprocessing, EurekaBio's CellSep® PRO for automated cell washing and concentration and EuLV™ system for lentiviral vector production. This combination delivers an end-to-end, modular yet functionally closed solution for GMP-compliant CAR-T production.

Developed with patients front of mind, this protocol is aiming to ensure more people will have better access to the most effective therapies possible.

Validated Performance: Faster, Higher Yield, and Enhanced Efficiency

• >1.2 × 10¹⁰ CAR-T cells produced in just 7–8 days across three healthy donors.
• Mean 44.9% transduction efficiency, nearly double that of manual flask controls (25.6%).
• 117-fold expansion on average, compared to 100-fold in manual controls.
• Preservation of critical TSCM (T stem cell memory) populations, known to support long-term persistence and clinical efficacy.
• High cell viability (>94%) and post-wash recovery (>88%) after processing with CellSep® PRO.

These results confirm the system's ability to consistently produce high-quality CAR-T cells in less time and with greater control compared to conventional open or semi-automated workflows. The new protocol has been published in Cytotherapy, showing the effective role of EurekaBio's CellSep® PRO and EuLV™ system in end-to-end CAR-T cell therapy manufacturing solutions.

About EurekaBio

EurekaBio is a prominent upstream core vendor in the Cell and Gene Therapy (CGT) field, specializing in innovative research and development of core technologies and key equipment. By integrating expertise across computer sciences, electronics, nanomaterials and chemical engineering with life sciences, EurekaBio is advancing next-generation tools and technologies to adress critical challenges in gene therapy, cell therapy and pharmaceutical R&D — pushing the frontiers of therapeutic innovation.

About Terumo Blood and Cell Technologies

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.